Share option awards and PDMR Dealing

IXICO

13/06/2025 08:03

RNS Number : 7630M

IXICO plc

13 June 2025

 

13 June 2025                                    

 

 

 

IXICO PLC

 

("IXICO" or the "Company")

 

Share Option Award & Director Bed & ISA Dealings

PDMR Dealing

 

Share Option Award:

 

IXICO plc (AIM: IXI), the medical imaging advanced analytics company delivering insights in neurosciences, today announces that it has issued a total of 850,000 options to subscribe for ordinary shares of 1 pence each in the Company (the "Share Options") to Mark Austin, Chief Technology Officer, James Chandler, Chief Business Officer and Terry Reilly, VP Global Business Development.  Mark Austin and James Chandler are considered Persons Discharging Managerial Responsibility under the Market Abuse Regulation (PDMRs) of the Company.

 

The Share Options have vesting criteria aligned with retention and annual share price growth over 3 years. The options have an exercise price equivalent to the closing share price on the date of award except for those awarded to PDMRs which have an exercise price of £0.01.  All options will be subject to a hold period to the third anniversary of their award.

 

The achievement of share price growth each year shall be measured by calculating the 3-month average share price immediately prior to each anniversary of the option award. The growth performance can be met in full by an absolute annual compound share price growth of 40% over the three-year period or in part by a 40% share price growth as compared to the prior year. In the first year this shall be compared to a baseline price equivalent to the three-month average share price immediately prior to 1 June 2025.

 

Director Bed & ISA Dealings:

 

In addition, the Company announces that it received notification on 12 June 2025, that Grant Nash, CFO/COO and PDMR, sold 45,263 ordinary shares of 1p each in the Company and repurchased 45,263 ordinary shares into Mr Nash's ISA account.  Following this transaction Mr Nash's beneficial interest in the Company's shares has not changed.

 

The notifications below, made in accordance with the requirements of the Market Abuse Regulation, provide further detail.

 

 

For further information please contact:

 

IXICO plc
+44 (0) 20 3763 7499
Bram Goorden, Chief Executive Officer
Grant Nash, Chief Financial Officer
James Chandler, Chief Business Officer (IR)
Cavendish Capital Markets Limited
(Nominated adviser and sole broker)
+44 (0) 20 7220 0500
Giles Balleny (Corporate Finance)
Nigel Birks (Life Sciences Specialist Sales)
Harriet Ward (Corporate Broking)
Michael F Johnson (Sales)


 

About IXICO

IXICO is dedicated to delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Huntington's disease, Parkinson's disease and Alzheimer's disease. The Company's purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience by supporting pharmaceutical companies across all phases of CNS clinical research. IXICO's goal is to be a leading advocate of artificial intelligence in medical image analysis.

 

IXICO has developed and deployed breakthrough data analytics, at scale, through its remote access technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for the Company's pharmaceutical clients.

 

More information is available on www.IXICO.com and follow us on X (formerly Twitter) @IXICOnews

 

1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Mark Austin
2
Reason for the notification
a)
Position/status
Chief Technology Officer and PDMR
b)
Initial notification /Amendment
Initial
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
IXICO plc
b)
LEI
2138005M1F59O6HWSA97
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Options over ordinary shares in IXICO plc
Identification code
ISIN: GB00BFXR4C20
b)
Nature of the transaction
Grant of Share Options
c)
Price(s) and volume(s)
Price(s)
Volume(s)
1 pence
350,000
d)
Aggregated information

 N/A - single transaction
- Aggregated volume
- Price
e)
Date of the transaction
12 June 2025
f)
Place of the transaction
Off Market Transaction

 

1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
James Chandler
2
Reason for the notification
a)
Position/status
Chief Business Officer and PDMR
b)
Initial notification /Amendment
Initial
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
IXICO plc
b)
LEI
2138005M1F59O6HWSA97
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Options over ordinary shares in IXICO plc
Identification code
ISIN: GB00BFXR4C20
b)
Nature of the transaction
Grant of Share Options
c)
Price(s) and volume(s)
Price(s)
Volume(s)
1 pence
350,000
d)
Aggregated information

 N/A - single transaction
- Aggregated volume
- Price
e)
Date of the transaction
12 June 2025
f)
Place of the transaction
Off Market Transaction

 

 

1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Grant Nash
2
Reason for the notification
a)
Position/status
Chief Financial Officer and PDMR
b)
Initial notification /Amendment
Initial
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
IXICO plc
b)
LEI
2138005M1F59O6HWSA97
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Ordinary shares in IXICO plc
Identification code
ISIN: GB00BFXR4C20
b)
Nature of the transaction
Sale and purchase of ordinary shares
c)
Price(s) and volume(s)
Price(s)
Volume(s)
Sale at 13.00p
45,263
Purchase at 13.04p
45,263
d)
Aggregated information

 N/A
- Aggregated volume
- Price
e)
Date of the transaction
12 June 2025
f)
Place of the transaction
Off Market Transaction

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 
  END

 

 
DSHDXLBFEQLBBBB